Piero Picci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6472280/publications.pdf

Version: 2024-02-01

314 papers	22,283 citations	5574 82 h-index	12597 132 g-index
317 all docs	317 docs citations	317 times ranked	16741 citing authors

#	Article	IF	Citations
1	Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. Journal of Clinical Oncology, 2001, 19, 1238-1247.	1.6	631
2	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. Journal of Clinical Oncology, 2015, 33, 3036-3046.	1.6	516
3	Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Cancer, 2006, 106, 1154-1161.	4.1	502
4	Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups. Journal of Clinical Oncology, 2005, 23, 8845-8852.	1.6	394
5	Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report. Journal of Clinical Oncology, 2000, 18, 4016-4027.	1.6	385
6	Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome. New England Journal of Medicine, 1995, 333, 1380-1385.	27.0	372
7	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology, The, 2017, 18, 812-822.	10.7	370
8	Osteosarcoma (Osteogenic sarcoma). Orphanet Journal of Rare Diseases, 2007, 2, 6.	2.7	364
9	Chordoma of the Mobile Spine: Fifty Years of Experience. Spine, 2006, 31, 493-503.	2.0	358
10	Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials, 2003, 24, 3095-3100.	11.4	351
11	The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation. PLoS Genetics, 2014, 10, e1004475.	3.5	335
12	Prognostic Factors in Nonmetastatic Ewingâ€™s Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli. Journal of Clinical Oncology, 2000, 18, 4-4.	1.6	309
13	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Annals of Oncology, 2012, 23, 508-516.	1.2	296
14	Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer, 1993, 72, 3227-3238.	4.1	285
15	Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival. Journal of Clinical Oncology, 2003, 21, 710-715.	1.6	277
16	Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. Cancer Research, 2005, 65, 3868-3876.	0.9	272
17	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncology, The, 2015, 16, 98-107.	10.7	270
18	Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor. Cancer, 1985, 56, 1515-1521.	4.1	260

#	Article	IF	Citations
19	Aneurysmal Bone Cyst of the Mobile Spine. Spine, 2001, 26, 27-35.	2.0	256
20	Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer, 1990, 65, 2539-2553.	4.1	230
21	Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics, 2009, 10, 625.	2.8	228
22	Chondrosarcoma of the Mobile Spine. Spine, 2000, 25, 804-812.	2.0	220
23	Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-Oncology, 2013, 15, 135-147.	1.2	190
24	<i>C-myc</i> and <i>c-fos</i> in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression. Oncology, 1998, 55, 556-563.	1.9	182
25	Histological heterogeneity of Ewingâ€™s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 397-411.	2.8	181
26	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	21.4	181
27	Massive Bone Allograft Reconstruction in High-Grade Osteosarcoma. Clinical Orthopaedics and Related Research, 2000, 377, 186-194.	1.5	180
28	Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1. Journal of Clinical Oncology, 2012, 30, 2112-2118.	1.6	165
29	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. Journal of Clinical Oncology, 2013, 31, 2303-2312.	1.6	161
30	Clinical outcome of central conventional chondrosarcoma. Journal of Surgical Oncology, 2012, 106, 929-937.	1.7	160
31	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics, 2012, 44, 323-327.	21.4	160
32	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Molecular Cancer, 2009, 8, 118.	19.2	159
33	Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers. Annals of Surgical Oncology, 2010, 17, 211-219.	1.5	159
34	Synovial sarcoma. Cancer, 2009, 115, 2988-2998.	4.1	156
35	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. Journal of Clinical Oncology, 2012, 30, 850-856.	1.6	156
36	Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone. Cancer, 1999, 86, 421-428.	4.1	155

#	Article	IF	Citations
37	CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. Journal of Clinical Investigation, 2010, 120, 668-680.	8.2	150
38	The treatment of osteosarcoma of the extremities: Twenty year's experience at the istituto ortopedico rizzoli. Cancer, 1981, 48, 1569-1581.	4.1	147
39	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. Journal of Clinical Oncology, 2020, 38, 2178-2186.	1.6	145
40	NVP-BEZ235 as a New Therapeutic Option for Sarcomas. Clinical Cancer Research, 2010, 16, 530-540.	7.0	142
41	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
42	Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Annals of Oncology, 2001, 12, 1145-1150.	1.2	138
43	Predictive factors for local recurrence in osteosarcoma 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthopaedica, 1998, 69, 230-236.	1.4	134
44	Mesenchymal chondrosarcoma of bone and soft tissues. Cancer, 1983, 52, 533-541.	4.1	132
45	miRâ€34a predicts survival of Ewing's sarcoma patients and directly influences cell chemoâ€sensitivity and malignancy. Journal of Pathology, 2012, 226, 796-805.	4.5	128
46	Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. European Journal of Cancer, 2005, 41, 2836-2845.	2.8	127
47	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. Clinical Cancer Research, 2007, 13, 1322-1330.	7.0	126
48	Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. Journal of Surgical Oncology, 2007, 96, 118-123.	1.7	126
49	Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta OncolÃ³gica, 2005, 44, 748-755.	1.8	124
50	Histologically verified lung metastases in benign giant cell tumoursâ€”14 cases from a single institution. International Orthopaedics, 2006, 30, 499-504.	1.9	124
51	Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer, 1993, 71, 338-345.	4.1	123
52	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewingâ€™s sarcoma. European Journal of Cancer, 2005, 41, 1349-1361.	2.8	123
53	Solid variant of aneurysmal bone cyst. Cancer, 1993, 71, 729-734.	4.1	121
54	Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome. Journal of Clinical Oncology, 2009, 27, 2209-2216.	1.6	121

#	Article	IF	Citations
55	Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer, 2010, 10, 462.	2.6	119
56	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 2011, 30, 2730-2740.	5.9	119
57	Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. European Journal of Cancer, 2005, 41, 2079-2085.	2.8	115
58	Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patientsâ€™ bed. Journal of Translational Medicine, 2013, 11, 268.	4.4	115
59	Overcoming Glutathione S-Transferase P1â€“Related Cisplatin Resistance in Osteosarcoma. Cancer Research, 2008, 68, 6661-6668.	0.9	113
60	Molecular mechanisms of CD99-induced caspase-independent cell death and cellâ€“cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene, 2004, 23, 5664-5674.	5.9	108
61	Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Annals of Oncology, 2011, 22, 1221-1227.	1.2	107
62	miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. International Journal of Oncology, 2013, 42, 667-675.	3.3	106
63	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Therapy, 2002, 9, 296-307.	4.6	101
64	Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Annals of Oncology, 1997, 8, 765-771.	1.2	100
65	Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer, 1993, 71, 1224-1230.	4.1	99
66	The Expression of ccn3(nov) Gene in Musculoskeletal Tumors. American Journal of Pathology, 2002, 160, 849-859.	3.8	99
67	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. European Journal of Cancer, 2015, 51, 210-217.	2.8	97
68	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. International Journal of Cancer, 2002, 101, 11-16.	5.1	96
69	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. Clinical Cancer Research, 2013, 19, 2117-2131.	7.0	96
70	Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities. Journal of Clinical Oncology, 2003, 21, 536-542.	1.6	95
71	Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes and Cancer, 2012, 51, 899-909.	2.8	95
72	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Human Pathology, 1996, 27, 408-416.	2.0	94

#	Article	IF	Citations
73	Targeting insulin-like growth factor 1 receptor in sarcomas. Current Opinion in Oncology, 2008, 20, 419-427.	2.4	94
74	Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. , 1999, 84, 489-493.		93
75	The role of surgical margins in treatment of Ewingâ€™s sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 766-772.	0.8	92
76	Emerging drugs for high-grade osteosarcoma. Expert Opinion on Emerging Drugs, 2010, 15, 615-634.	2.4	92
77	Oncogene alterations in primary, recurrent, and metastatic human bone tumors. Journal of Cellular Biochemistry, 1996, 63, 37-50.	2.6	91
78	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene, 2005, 24, 4349-4361.	5.9	90
79	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
80	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Annals of Oncology, 2016, 27, 2283-2288.	1.2	90
81	Malignancy in Giant Cell Tumor of Bone: A Review of the Literature. Technology in Cancer Research and Treatment, 2019, 18, 153303381984000.	1.9	89
82	Osteosarcoma of the Bones of the Footâ€”an Easily Misdiagnosed Malignant Tumor. Mayo Clinic Proceedings, 1998, 73, 842-847.	3.0	88
83	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
84	Tumor response assessment by modified Choi criteria in localized highâ€risk soft tissue sarcoma treated with chemotherapy. Cancer, 2012, 118, 5857-5866.	4.1	85
85	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori, 2018, 104, 30-36.	1.1	84
86	Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer, 2014, 120, 3159-3164.	4.1	83
87	Advances in emerging drugs for osteosarcoma. Expert Opinion on Emerging Drugs, 2015, 20, 495-514.	2.4	82
88	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. Cancer Research, 2007, 67, 7675-7685.	0.9	81
89	Neoadjuvant Chemotherapy for Extremity Osteosarcoma: Preliminary Results of the Rizzoli's 4th Study. Acta OncolÃ³gica, 1998, 37, 41-48.	1.8	78
90	Redundancy of autocrine loops in human osteosarcoma cells. , 1999, 80, 581-588.		78

#	Article	IF	Citations
91	The treatment of localized Ewing's sarcoma: The experience at the istituto ortopedico rizzoli in 163 cases treated with and without adjuvant chemotherapy. Cancer, 1982, 49, 1561-1570.	4.1	75
92	Osteoid osteoma and osteoblastoma of the talus. Skeletal Radiology, 1986, 15, 360-364.	2.0	74
93	Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. Spine, 2016, 41, 1049-1057.	2.0	74
94	<scp>CIC</scp>â€“<scp>DUX</scp>4 fusionâ€positive roundâ€cell sarcomas of soft tissue and bone: a singleâ€institution morphological and molecular analysis of seven cases. Histopathology, 2016, 69, 624-634.	2.9	73
95	Nonmetastatic Osteosarcoma of the Extremity: Results of a Neoadjuvant Chemotherapy Protocol (IOR/OS-3) with High-dose Methotrexate, Intraarterial or Intravenous Cisplatin, Doxorubicin, and Salvage Chemotherapy Based on Histologic Tumor Response. Tumori, 1999, 85, 458-464.	1.1	71
96	c-kit Receptor Expression in Ewingâ€™s Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. Journal of Clinical Oncology, 2003, 21, 1952-1960.	1.6	71
97	High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients. ISRN Oncology, 2011, 2011, 1-10.	2.1	71
98	Molecular Diagnosis in Ewing Family Tumors. Journal of Molecular Diagnostics, 2011, 13, 313-324.	2.8	70
99	Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewingâ€™s sarcoma. European Journal of Cancer, 2006, 42, 91-96.	2.8	69
100	Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Molecular BioSystems, 2012, 8, 994-1006.	2.9	69
101	Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes and Cancer, 2015, 54, 565-574.	2.8	69
102	Neoadjuvant chemotherapy for Ewing's sarcoma of bone. , 1998, 82, 1174-1183.		68
103	Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma. Cancer Research, 2014, 74, 6578-6588.	0.9	66
104	Localized Ewing's sarcoma of bone: Ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy. European Journal of Cancer & Clinical Oncology, 1985, 21, 163-173.	0.7	63
105	Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. , 2000, 85, 782-786.		63
106	Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60. Cancer, 2007, 109, 780-786.	4.1	62
107	Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival. Clinical Cancer Research, 2009, 15, 3550-3556.	7.0	62
108	Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. European Journal of Cancer & Clinical Oncology, 1986, 22, 1337-1345.	0.7	61

#	Article	IF	Citations
109	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. International Journal of Cancer, 2004, 108, 358-366.	5.1	61
110	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	10.7	61
111	CD99 Acts as an Oncosuppressor in Osteosarcoma. Molecular Biology of the Cell, 2006, 17, 1910-1921.	2.1	60
112	Osteosarcoma of the Mobile Spine. Spine, 2012, 37, E381-E386.	2.0	60
113	Giant cell reparative granuloma and other giant cell lesions of the bones of the hands and feet. Skeletal Radiology, 1986, 15, 415-421.	2.0	59
114	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo EspaÃ±ol de InvestigaciÃ³n en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. Journal of Clinical Oncology, 2015, 33, 3628-3634.	1.6	59
115	Prognostic Value of CCN3 in Osteosarcoma. Clinical Cancer Research, 2008, 14, 701-709.	7.0	58
116	Palliative therapy for osteosarcoma. Expert Review of Anticancer Therapy, 2011, 11, 217-227.	2.4	58
117	Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer, 2009, 9, 17.	2.6	57
118	Vascular bone tumors: a proposal of a classification based on clinicopathological, radiographic and genetic features. Skeletal Radiology, 2012, 41, 1495-1507.	2.0	57
119	NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion. Journal of Molecular Cell Biology, 2013, 5, 176-193.	3.3	55
120	Defining Ewing and Ewing-like small round cell tumors (SRCT): The need for molecular techniques in their categorization and differential diagnosis. A study of 200 cases. Annals of Diagnostic Pathology, 2016, 22, 25-32.	1.3	55
121	Therapy for primary non-Hodgkin's lymphoma of bone and a comparison of results with ewing's sarcoma. Ten years' experience at the Istituto Ortopedico Rizzoli. Cancer, 1986, 57, 1468-1472.	4.1	53
122	Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma. Molecular Endocrinology, 2012, 26, 1603-1616.	3.7	53
123	Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFÎ² as Potential Targets. American Journal of Pathology, 2013, 182, 1347-1356.	3.8	53
124	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewingâ€™s sarcoma family of tumors (ESFT). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 815-824.	2.8	53
125	Metastatic Patterns in Osteosarcoma. Tumori, 1988, 74, 421-427.	1.1	52
126	The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 215-223.	6.4	52

#	Article	IF	Citations
127	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Scientific Reports, 2019, 9, 12174.	3.3	52
128	Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors. International Journal of Cancer, 2011, 128, 1139-1150.	5.1	51
129	The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathology Research and Practice, 2016, 212, 811-816.	2.3	51
130	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. Nature Communications, 2018, 9, 3184.	12.8	50
131	Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcomaFindings in 42 patients followed for 1â€“16 years. Acta Orthopaedica, 2004, 75, 487-491.	1.4	49
132	Second Malignancy in 597 Patients With Ewing Sarcoma of Bone Treated at a Single Institution With Adjuvant and Neoadjuvant Chemotherapy Between 1972 and 1999. Journal of Pediatric Hematology/Oncology, 2005, 27, 517-520.	0.6	49
133	Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy The Rizzoli experience in 52 patients. Monthly Notices of the Royal Astronomical Society: Letters, 2006, 77, 938-943.	3.3	49
134	Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. International Journal of Cancer, 2006, 119, 1039-1046.	5.1	49
135	Expression of insulin-like growth factor system components in Ewingâ€™s sarcoma and their association with survival. European Journal of Cancer, 2011, 47, 1258-1266.	2.8	49
136	Small Cell Osteosarcoma. American Journal of Surgical Pathology, 2015, 39, 691-699.	3.7	49
137	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. European Journal of Cancer, 2018, 93, 28-36.	2.8	49
138	Histologic Response of High-Grade Nonmetastatic Osteosarcoma of the Extremity to Chemotherapy. Clinical Orthopaedics and Related Research, 2001, 386, 186-196.	1.5	48
139	Involvement ofINK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer, 2001, 92, 3062-3067.	4.1	47
140	Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1^{Â®} can Overcome Drug Resistance in Osteosarcoma. Current Cancer Drug Targets, 2016, 16, 261-274.	1.6	47
141	Mechanisms of gene amplification and evidence of coamplification in drugâ€resistant human osteosarcoma cell lines. Genes Chromosomes and Cancer, 2009, 48, 289-309.	2.8	46
142	Neoadjuvant chemotherapy in highâ€risk soft tissue sarcomas: A Sarculatorâ€based risk stratification analysis of the ISGâ€STS 1001 randomized trial. Cancer, 2022, 128, 85-93.	4.1	46
143	Analysis of 12q13-15 Genes in Parosteal Osteosarcoma. Clinical Orthopaedics and Related Research, 2000, 377, 195-204.	1.5	45
144	NG2 expression predicts the metastasis formation in softâ€tissue sarcoma patients. Journal of Orthopaedic Research, 2009, 27, 135-140.	2.3	45

#	Article	IF	Citations
145	Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. Genes Chromosomes and Cancer, 1998, 23, 213-219.	2.8	44
146	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget, 2017, 8, 111836-111846.	1.8	44
147	Radiological features of 24 periosteal chondrosarcomas. Skeletal Radiology, 2001, 30, 208-212.	2.0	43
148	Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Letters, 2007, 250, 194-205.	7.2	43
149	Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug. PLoS ONE, 2013, 8, e83832.	2.5	43
150	Primary High-Grade Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2005, 27, 129-134.	0.6	42
151	Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. European Journal of Cancer, 2006, 42, 1172-1180.	2.8	42
152	Difficulty distinguishing benign notochordal cell tumor from chordoma further suggests a link between them. Cancer Imaging, 2014, 14, 4.	2.8	42
153	CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin. Clinical Cancer Research, 2015, 21, 146-156.	7.0	42
154	Identification of Potential Biomarkers for Giant Cell Tumor of Bone Using Comparative Proteomics Analysis. American Journal of Pathology, 2011, 178, 88-97.	3.8	41
155	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget, 2016, 7, 61970-61987.	1.8	41
156	CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget, 2016, 7, 79925-79942.	1.8	40
157	Increased C-MYC Oncogene Expression in Ewing's Sarcoma: Correlation with Ki67 Proliferation Index. Tumori, 1999, 85, 167-173.	1.1	39
158	Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents. Clinical Cancer Research, 2015, 21, 1373-1382.	7.0	39
159	Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clinical Cancer Research, 2002, 8, 3893-903.	7.0	39
160	Prognostic relevance of C-mycgene expression in giant-cell tumor of bone. Journal of Orthopaedic Research, 1998, 16, 1-7.	2.3	38
161	Second Malignant Neoplasm in Patients With Osteosarcoma of the Extremities Treated With Adjuvant and Neoadjuvant Chemotherapy. Journal of Pediatric Hematology/Oncology, 2006, 28, 774-780.	0.6	38
162	The t(X;6) in subungual exostosis results in transcriptional deregulation of the gene for insulin receptor substrate 4. International Journal of Cancer, 2011, 128, 487-491.	5.1	37

#	Article	IF	Citations
163	CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research, 2014, 29, 1295-1309.	2.8	37
164	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R. Frontiers in Endocrinology, 2018, 9, 178.	3.5	37
165	The Treatment of Nonmetastatic High Grade Osteosarcoma of the Extremity: Review of the Italian Rizzoli Experience. Impact on the Future. Cancer Treatment and Research, 2009, 152, 275-287.	0.5	37
166	Treatment Recommendations for Osteosarcoma and Adult Soft Tissue Sarcomas. Drugs, 1994, 47, 82-92.	10.9	36
167	Malignant fibrous histiocytoma: Inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22?evidence for a common genetic defect. Genes Chromosomes and Cancer, 2000, 27, 191-195.	2.8	36
168	Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. European Journal of Cell Biology, 2003, 82, 483-493.	3.6	36
169	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	5.9	35
170	Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities in Preadolescent Patients. Journal of Pediatric Hematology/Oncology, 2008, 30, 908-912.	0.6	35
171	p53-Dependent Activation of microRNA-34a in Response to Etoposide-Induced DNA Damage in Osteosarcoma Cell Lines Not Impaired by Dominant Negative p53 Expression. PLoS ONE, 2014, 9, e114757.	2.5	35
172	Surgical treatment and results of 62 patients with epithelioid hemangioendothelioma of bone. Journal of Surgical Oncology, 2014, 109, 791-797.	1.7	35
173	Primary Angiosarcoma of Bone. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 528-534.	1.3	34
174	MDM2 and CDK4 expression in periosteal osteosarcoma. Human Pathology, 2015, 46, 549-553.	2.0	34
175	Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone, 2004, 34, 672-679.	2.9	33
176	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy. Clinical Cancer Research, 2018, 24, 3704-3716.	7.0	33
177	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892.	4.1	33
178	Prognostic relevance of CCN3 in Ewing sarcoma. Human Pathology, 2009, 40, 1479-1486.	2.0	32
179	Telangiectatic osteosarcoma: a review of 87 cases. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2197-2207.	2.5	32
180	Î±-Tocopheryl succinate alters cell cycle distribution sensitising human osteosarcoma cells to methotrexate-induced apoptosis. Cancer Letters, 2006, 232, 226-235.	7.2	31

#	Article	IF	Citations
181	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactosideâ€binding soluble 3 binding protein (LGALS3BP). International Journal of Cancer, 2010, 126, 41-52.	5.1	31
182	Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors. Clinical Cancer Research, 2013, 19, 2473-2485.	7.0	31
183	Primary pseudomyogenic haemangioendothelioma of bone: report of two cases. Skeletal Radiology, 2015, 44, 727-731.	2.0	31
184	Genomeâ€wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	5.1	31
185	Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. Cancer Management and Research, 2018, Volume 10, 49-60.	1.9	31
186	Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLoS ONE, 2016, 11, e0166233.	2.5	31
187	Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncology Reports, 2003, 10, 351-6.	2.6	31
188	Troglitazione affects survival of human osteosarcoma cells. International Journal of Cancer, 2002, 98, 344-351.	5.1	30
189	Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41â€“60 years. Monthly Notices of the Royal Astronomical Society: Letters, 2007, 78, 377-384.	3.3	30
190	Enchondroma vs. chondrosarcoma: A simple, easy-to-use, new magnetic resonance sign. European Journal of Radiology, 2013, 82, 2154-2160.	2.6	30
191	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. Molecular Cancer Therapeutics, 2014, 13, 249-259.	4.1	30
192	Altered G1 phase regulation in osteosarcoma. , 1997, 74, 518-522.		29
193	Predictive Factors of Histologic Response to Primary Chemotherapy in Patients With Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2007, 29, 364-368.	0.6	29
194	Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Investigational New Drugs, 2014, 32, 1167-1180.	2.6	28
195	Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?. Orphanet Journal of Rare Diseases, 2015, 10, 6.	2.7	28
196	MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. Histology and Histopathology, 2013, 28, 671-8.	0.7	28
197	Intracortical osteosarcoma: Rare entity or early manifestation of classical osteosarcoma?. Skeletal Radiology, 1983, 9, 255-258.	2.0	27
198	Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation. Oncology Reports, 2014, 31, 370-375.	2.6	27

#	Article	IF	Citations
199	Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study. Journal of Orthopaedic Research, 2015, 33, 1205-1211.	2.3	27
200	Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. BioTechniques, 2012, 0, 1-7.	1.8	27
201	Radiological study of 12 high-grade surface osteosarcomas. Skeletal Radiology, 2001, 30, 667-671.	2.0	26
202	Adjuvant chemotherapy for soft tissue sarcoma. Current Opinion in Oncology, 2005, 17, 361-365.	2.4	26
203	Diagnostic Utility of Molecular Investigation in Extraskeletal Myxoid Chondrosarcoma. Journal of Molecular Diagnostics, 2014, 16, 314-323.	2.8	26
204	Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAPâ€35). International Journal of Cell Cloning, 1990, 8, 409-424.	1.6	25
205	Î±-Tocopheryl succinate induces cytostasis and apoptosis in osteosarcoma cells: the role of E2F1. Biochemical and Biophysical Research Communications, 2005, 331, 1515-1521.	2.1	25
206	Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines. Frontiers in Endocrinology, 2015, 6, 74.	3.5	25
207	Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 109-120.	2.8	24
208	Excision repair crossâ€complementation group 1 protein expression predicts survival in patients with highâ€grade, nonâ€metastatic osteosarcoma treated with neoadjuvant chemotherapy. Histopathology, 2015, 67, 338-347.	2.9	24
209	Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. Pharmacogenomics, 2016, 17, 2097-2114.	1.3	24
210	Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors. Pathology Research and Practice, 2017, 213, 1048-1053.	2.3	24
211	Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability. Modern Pathology, 2010, 23, 359-366.	5.5	23
212	Late sarcoma development after curettage and bone grafting of benign bone tumors. European Journal of Radiology, 2011, 77, 19-25.	2.6	23
213	Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. Future Oncology, 2017, 13, 673-677.	2.4	23
214	Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation. Cell Death and Disease, 2019, 10, 471.	6.3	23
215	Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group. Annals of Surgical Oncology, 2021, 28, 1142-1150.	1.5	23
216	Prognostic Value of Serum Alkaline Phosphatase in Osteosarcoma. Tumori, 1987, 73, 331-336.	1.1	22

#	Article	IF	Citations
217	Murine model for skeletal metastases of Ewing's sarcoma. Journal of Orthopaedic Research, 2000, 18, 959-966.	2.3	22
218	Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. European Journal of Cell Biology, 2004, 83, 483-491.	3.6	22
219	Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases. Histopathology, 2010, 57, 59-72.	2.9	22
220	Epithelial marker expression does not rule out a diagnosis of Ewingâ€™s sarcoma family of tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 409-414.	2.8	22
221	Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. Genes Chromosomes and Cancer, 2011, 50, 291-306.	2.8	22
222	Receptor tyrosine kinase pathway analysis sheds light on similarities between clearâ€cell sarcoma and metastatic melanoma. Genes Chromosomes and Cancer, 2012, 51, 111-126.	2.8	22
223	Significant association between human osteosarcoma and simian virus 40. Cancer, 2015, 121, 708-715.	4.1	22
224	High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. Cells, 2020, 9, 2389.	4.1	22
225	Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. International Journal of Cancer, 2000, 87, 328-335.	5.1	21
226	Xg Expression in Ewing's Sarcoma Is of Prognostic Value and Contributes to Tumor Invasiveness. Cancer Research, 2010, 70, 3730-3738.	0.9	21
227	Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 333-337.	2.8	21
228	Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy. Analytical Cellular Pathology, 2011, 34, 131-145.	1.4	20
229	Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. Histopathology, 2011, 59, 376-389.	2.9	20
230	Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. Clinical and Experimental Metastasis, 2014, 31, 15-24.	3.3	20
231	p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. Human Pathology, 2016, 58, 15-23.	2.0	20
232	Soft Tissue Tumors Rarely Presenting Primary in Bone; Diagnostic Pitfalls. Surgical Pathology Clinics, 2017, 10, 705-730.	1.7	20
233	Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients. Human Pathology, 2019, 91, 11-18.	2.0	20
234	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal of Oncology, 2006, 29, 1459-68.	3.3	20

#	Article	IF	Citations
235	Case report 489. Skeletal Radiology, 1988, 17, 432-435.	2.0	19
236	Predictive Factors of Histological Response to Primary Chemotherapy in Ewing's Sarcoma. Acta OncolÃ³gica, 1998, 37, 671-676.	1.8	19
237	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal of Oncology, 2006, 29, 1459.	3.3	19
238	Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. International Journal of Radiation Oncology Biology Physics, 2007, 67, 505-511.	0.8	19
239	Classic Osteosarcoma. , 2014, , 147-152.		19
240	Comparison of the Outcome of Conventional Osteosarcoma at Two Specialist International Orthopaedic Oncology Centres. Sarcoma, 2004, 8, 13-18.	1.3	18
241	Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 665-671.	2.8	18
242	miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. Cellular Oncology (Dordrecht), 2017, 40, 77-88.	4.4	18
243	Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewingâ€™s Sarcoma Tumor Cells. Current Pharmaceutical Biotechnology, 2013, 14, 449-463.	1.6	18
244	Osteosarcoma of the Pelvis: A Monoinstitutional Experience in Patients Younger than 41 Years. Tumori, 2012, 98, 702-708.	1.1	17
245	Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro-Oncology, 2015, 17, 63-69.	1.2	17
246	Osteosarcoma follow-up: chest X-ray or computed tomography?. Clinical Sarcoma Research, 2017, 7, 3.	2.3	17
247	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). Tumori, 2014, 100, 612-619.	1.1	17
248	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). Tumori, 2014, 100, 612-9.	1.1	17
249	Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Analytical Cellular Pathology, 2011, 34, 131-45.	1.4	17
250	Full-lung tomograms and bone scanning in the initial work-up of patients with osteogenic sarcoma. A review of 126 cases. European Journal of Cancer & Clinical Oncology, 1982, 18, 967-971.	0.7	16
251	Presence and expression of the Simian virus-40 genome in human giant cell tumors of bone. , 2000, 28, 23-30.		16
252	Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of boneâ€”An array comparative genomic hybridization study. Genes Chromosomes and Cancer, 2010, 49, 132-143.	2.8	16

#	Article	IF	Citations
253	Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 299-311.	3.3	16
254	Prognostic Significance of Nuclear Accumulation of c-myc and mdm2 Proteins in Synovial Sarcoma of the Extremities. Oncology, 2000, 58, 253-260.	1.9	15
255	Vincristine, Doxorubicin, Cyclophosfamide, Actinomycin D, Ifosfamide, and Etoposide in Adult and Pediatric Patients with Nonmetastatic Ewing Sarcoma. Final Results of a Monoinstitutional Study. Tumori, 2010, 96, 213-218.	1.1	15
256	Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis. PLoS ONE, 2014, 9, e107105.	2.5	15
257	miR-196a expression in human and canine osteosarcomas: A comparative study. Research in Veterinary Science, 2015, 99, 112-119.	1.9	15
258	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. Cancers, 2021, 13, 1053.	3.7	15
259	The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences. Oncotarget, 2017, 8, 63121-63131.	1.8	15
260	No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anti-Cancer Drugs, 2006, 17, 411-415.	1.4	14
261	Prognostic Value of P-Glycoprotein in High-Grade Osteosarcoma. Journal of Clinical Oncology, 2007, 25, 4858-4860.	1.6	14
262	Copy number alterations and neoplasiaâ€specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. Genes Chromosomes and Cancer, 2014, 53, 579-588.	2.8	14
263	Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection. Pathology Research and Practice, 2014, 210, 508-513.	2.3	14
264	Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 245-257.	3.3	14
265	Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma. American Journal of Cancer Research, 2015, 5, 3446-54.	1.4	14
266	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer, 2014, 14, 137.	2.6	13
267	Ewing Sarcoma in Patients over 40 Years of Age: A Prospective Analysis of 31 Patients Treated at a Single Institution. Tumori, 2016, 102, 481-487.	1.1	13
268	In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival. Bone, 2019, 127, 188-198.	2.9	13
269	Neoadjuvant Chemotherapy for High Grade Malignant Fibrous Histiocytoma of Bone. Clinical Orthopaedics and Related Research, 1998, 346, 178???189.	1.5	12
270	DNA copy number amplifications in sarcomas with homogeneously staining regions and double minutes. Cytometry, 2001, 46, 79-84.	1.8	12

#	Article	IF	Citations
271	Evaluation of the molecular mechanisms involved in the gain of function of a Li-FraumeniTP53 Mutation. Human Mutation, 2005, 26, 94-103.	2.5	12
272	Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy. Oncology Reports, 2017, 37, 1387-1393.	2.6	12
273	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. Expert Review of Molecular Diagnostics, 2018, 18, 947-961.	3.1	12
274	Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1703-1713.	3.0	12
275	Phase 2 study for nonmetastatic extremity highâ€grade osteosarcoma in pediatric and adolescent and young adult patients with a riskâ€adapted strategy based on ABCB1/Pâ€glycoprotein expression: An Italian Sarcoma Group trial (ISG/OSâ€2). Cancer, 2022, 128, 1958-1966.	4.1	12
276	Primary Chemotherapy and Delayed Surgery for Malignant Fibrous Histiocytoma of Bone in the Extremity. Tumori, 1990, 76, 537-542.	1.1	11
277	Fibrocartilaginous mesenchymoma of bone: a singleâ€institution experience with molecular investigations and a review of the literature. Histopathology, 2017, 71, 134-142.	2.9	11
278	Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Modern Pathology, 2018, 31, 1694-1707.	5.5	11
279	Identification of novel candidate circulating biomarkers for malignant soft tissue sarcomas: Correlation with metastatic progression. Proteomics, 2016, 16, 689-697.	2.2	10
280	Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). Scientific Reports, 2020, 10, 10853.	3.3	10
281	4-Demethoxy-3â€²-deamino-3â€²-aziridinyl-4â€²-methylsulphonyl-daunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients. European Journal of Cancer, 2005, 41, 2184-2195.	2.8	9
282	Changes inp14ARF do not play a primary role in human chondrosarcoma tissues. International Journal of Cancer, 2001, 93, 703-705.	5.1	8
283	Design and construction of a new human naÃ¯ve single-chain fragment variable antibody library, IORISS1. Journal of Biotechnology, 2016, 224, 1-11.	3.8	8
284	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. Bone Marrow Transplantation, 2018, 53, 591-599.	2.4	8
285	Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years. Tumori, 2012, 98, 702-8.	1.1	8
286	Staging, Therapy and Prognosis of Primary Non-Hodgkin's Lymphoma of Bone and a Comparison of Results with Localized Ewing's Sarcoma: Ten Years Experience at the Istituto Ortopedico Rizzoli. Tumori, 1985, 71, 345-354.	1.1	7
287	Case report 301. Skeletal Radiology, 1985, 13, 228-232.	2.0	6
288	Case report 629. Skeletal Radiology, 1990, 19, 461-464.	2.0	6

#	Article	IF	Citations
289	Correlation between Apoptosis and TP53 Status in Osteosarcoma. Cancer Genetics and Cytogenetics, 1998, 105, 177-181.	1.0	6
290	Serum Antibodies Against Simian Virus 40 Large T Antigen, the Viral Oncoprotein, in Osteosarcoma Patients. Frontiers in Cell and Developmental Biology, 2018, 6, 64.	3.7	6
291	CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression. Oncotarget, 2016, 7, 77958-77967.	1.8	6
292	Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors. Neuro-Oncology, 2014, 16, 320-322.	1.2	5
293	Circulating Candidate Biomarkers in Giant Cell Tumors of Bone. Proteomics - Clinical Applications, 2018, 12, e1800041.	1.6	5
294	Unlocking bone for proteomic analysis and FISH. Laboratory Investigation, 2019, 99, 708-721.	3.7	5
295	Neuroendocrine differentiation in a large series of genetically-confirmed Ewingâ€™s sarcoma family tumor: Does it provide any diagnostic or prognostic information?. Pathology Research and Practice, 2021, 219, 153362.	2.3	5
296	Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. Cancers, 2021, 13, 3046.	3.7	5
297	Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools. European Journal of Surgical Oncology, 2021, 47, 1778-1783.	1.0	5
298	Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure. Tumori, 2021, , 030089162110530.	1.1	5
299	Clinical Significance of Tumor Protein D52 Immunostaining in a Large Series of Ewing's Sarcoma Family of Tumors. Pediatric and Developmental Pathology, 2011, 14, 255-256.	1.0	4
300	Staging and treatment of primary tumors of the spine. Current Opinion in Orthopaedics, 1999, 10, 93-100.	0.3	3
301	Osteosarcoma: What did we learn from the paediatric experience for adolescents and young adults?. European Journal of Cancer, Supplement, 2007, 5, 227-234.	2.2	3
302	Cell Cycle Regulatory Protein Expression in Multinucleated Giant Cells of Giant Cell Tumor of Bone: do They Proliferate?. Pathology and Oncology Research, 2021, 27, 643146.	1.9	3
303	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. Molecular Cancer Therapeutics, 2021, 20, 2539-2552.	4.1	2
304	Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study.. Journal of Clinical Oncology, 2020, 38, 10517-10517.	1.6	2
305	Frontâ€line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. Pediatric Blood and Cancer, 2017, 64, e26650.	1.5	1
306	Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. Cancers, 2021, 13, 2789.	3.7	1

#	Article	IF	Citations
307	Secondary Osteosarcoma. , 2014, , 157-158.		1
308	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1
309	Case Report 301. Skeletal Radiology, 1985, 13, 94-95.	2.0	0
310	Case report 489. Skeletal Radiology, 1988, 17, 315-316.	2.0	0
311	Response to the letter by Dr Klein. Skeletal Radiology, 2010, 39, 71-71.	2.0	0
312	Prognostic Relevance of CCN3 in Bone Sarcomas. , 2010, , 223-243.		0
313	Fibroblastic/Myofibroblastic Tumors. , 2020, , 241-272.		0
314	Osteosarcomas (OS). , 2020, , 185-212.		0